NCT04818333View on ClinicalTrials.gov

A Study of SHR-A1811 in Subjects With Advanced Non-small Cell Lung Cancer

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

157

Participants

Timeline

Start Date

April 23, 2021

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2025

Conditions

Advanced Non-small Cell Lung Cancer

Interventions

DRUG

SHR-A1811

Phase 1 Drug: SHR-A1811 There are four pre-defined dose regimens . Subjects will be enrolled with an initial dose Phase 2 Drug: SHR-A1811 Doses will be determined from Phase 1

Trial Locations (1)

200030

Shanghai Chest Hospital, Shanghai

All Listed Sponsors

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY